Research Article Volume 15 Issue 1 - 2026

Clinical Interplay Between Chronic Obstructive Pulmonary Disease and Chronic Kidney Disease: A Cross-Sectional Analysis of 79 Patients

Petar Avramovski1*, Igor Nedelkovski2, Liljana Todorovska3, Maja Avramovska4, Zorica Nikleski5, Stefan Talev6, Svetlana Stefanovska7 and Biljana Taleva8

1Department of Internal Medicine, Clinical Hospital - Bitola, St. Clement of Ohrid University, Bitola, North Macedonia

2Department of Anesthesia and Intensive Care, Clinical Hospital - Bitola, North Macedonia

3Department of Nuclear Medicine, Clinical Hospital - Bitola, North Macedonia

4Department of Gynecology and Obstetrics, Clinical Hospital - Bitola, North Macedonia

5Medico - Legal Department, MedAssess, Sydney, New South Wales, Australia

6Department of Chirurgie, Clinical Hospital - Bitola, North Macedonia

7Department of Internal Medicine and Department of Cardiology, Clinical Hospital - Bitola, Bitola, North Macedonia

8Department of Vascular Surgery, PHI University Clinic for Surgical Diseases “St. Naum Ohridski - Skopje”, Skopje, North Macedonia

*Corresponding Author: Petar Avramovski, Department of Internal Medicine, Clinical Hospital - Bitola, St. Clement of Ohrid University, Bitola, North Macedonia.
Received: November 25, 2025; Published: December 15, 2025



Background: Chronic Obstructive Pulmonary Disease (COPD) and Chronic Kidney Disease (CKD) often coexist, sharing risk factors and pathophysiological mechanisms such as systemic inflammation and oxidative stress. Their overlap may worsen disease progression and complicate management.

Objective: To evaluate the clinical, laboratory, and functional characteristics of patients with coexisting COPD and mild CKD, and to assess correlations between renal and pulmonary function.

Methods: A cross-sectional study included 79 patients with mildly impaired renal function (eGFR 78.7 ± 10.3 mL/min/1.73m2) and respiratory symptoms. Demographics, laboratory data (urea, creatinine, hemoglobin, erythrocytes), and spirometric parameters-FVC, FEV1, FEV1/FVC, PEF, ELA, FEV25-75, FET, FIVC, FEV1/VC-were analyzed. Pearson correlation evaluated associations between renal and pulmonary function.

Results: Patients had a mean age of 43.2 ± 15.6 year. Laboratory results confirmed mild renal impairment (urea 6.74 ± 1.93 mmol/L, creatinine 95.2 ± 13.8 μmol/L, hemoglobin 98.1 ± 13.2 g/L, erythrocytes 4.51 ± 0.46 ×1012/L). Pulmonary function was reduced (FVC 1.49 ± 0.13 L, FEV1 1.21 ± 0.09 L, PEF 2.42 ± 0.31 L/s, FEV25-75 1.16 ± 0.19 L/s). Significant positive correlations were observed between eGFR and FVC (r = 0.271, p = 0.015), FEV1 (r = 0.299, p = 0.007), PEF (r = 0.227, p = 0.044), FIVC (r = 0.241, p = 0.032), FEV25-75 (r = 0.332, p = 0.003), and ELA (r = 0.286, p = 0.011).

Conclusion: Mild CKD in patients with COPD is associated with measurable declines in pulmonary function. These findings highlight the clinical interplay between kidney and lung health, supporting early recognition and integrated multidisciplinary management to optimize outcomes.

 Keywords: Chronic Kidney Disease; Chronic Obstructive Pulmonary Disease; Spirometry; Estimated Glomerular Filtration Rate, Pulmonary Age

  1. Liu Z., et al. “Association between COPD and CKD: a systematic review and meta analysis”. Frontiers in Public Health 12 (2024): 1494291.
  2. Corrado Pelaia., et al. “Predictors of renal function worsening in patients with chronic obstructive pulmonary disease (COPD). Multicenter study, 707 patients”. Nutrients8 (2021): 2811.
  3. Jia Wei., et al. “Association between serum interleukin 6 concentrations and chronic obstructive pulmonary disease: a meta-analysis”. PeerJ 3 (2015): e1199.
  4. Francisco Garcia-Rio., et al. “Systemic inflammation in chronic obstructive pulmonary disease: a population based study”. Respiratory Research 1 (2010): 63.
  5. Renata Ferrari., et al. “Three-year follow-up of interleukin 6 and C-reactive protein in COPD”. Respiratory Research 14 (2013): 24.
  6. Hui Huang., et al. “Interleukin 6 is a strong predictor of the frequency of COPD exacerbation within 1 year”. International Journal of Chronic Obstructive Pulmonary Disease 16 (2021): 2945-2951.
  7. Francesca Tinti., et al. “Chronic kidney disease as a systemic inflammatory syndrome: update on mechanisms involved and potential treatment”. Life (Basel) 11 (2021): 419.
  8. Victor M Baião., et al. “Effects of exercise on inflammatory markers in individuals with chronic kidney disease: a systematic review and meta analysis”. Metabolites7 (2023): 795.
  9. Michal L Melamed and Kalani L Raphael. “Metabolic acidosis in CKD: A review of recent findings”. Kidney Medicine 2 (2021): 267-277.
  10. Donald E Wesson., et al. “Mechanisms of metabolic acidosis-induced kidney injury in chronic kidney disease”. Journal of the American Society of Nephrology3 (2020): 469-482.
  11. Hyo Jin Kim. “Metabolic acidosis in chronic kidney disease: pathogenesis, clinical consequences, and treatment”. Electrolytes and Blood Pressure 2 (2021): 29-37.
  12. Chatrenet A., et al. “Analysis of the rate of force development reveals high neuromuscular fatigability in elderly patients with chronic kidney disease”. ar Xiv. (2023): 2307.10691.
  13. Avramovski P., et al. “The effect of chronic pulmonary disease and aortic stiffness”. EC Pulmonology and Respiratory Medicine2 (2017): 59-66.

Petar Avramovski., et al. “Clinical Interplay Between Chronic Obstructive Pulmonary Disease and Chronic Kidney Disease: A Cross-Sectional Analysis of 79 Patients”. EC Pulmonology and Respiratory Medicine  15.1 (2026): 01-06.